Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Free Cash Flow (2016 - 2025)

Coherus Oncology's Free Cash Flow history spans 13 years, with the latest figure at -$28.1 million for Q4 2025.

  • For Q4 2025, Free Cash Flow fell 198.2% year-over-year to -$28.1 million; the TTM value through Dec 2025 reached $331.8 million, up 59.99%, while the annual FY2025 figure was $331.8 million, 59.99% up from the prior year.
  • Free Cash Flow for Q4 2025 was -$28.1 million at Coherus Oncology, up from -$46.3 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at $436.8 million in Q2 2025 and bottomed at -$100.0 million in Q4 2022.
  • The 5-year median for Free Cash Flow is -$34.0 million (2022), against an average of $4.1 million.
  • The largest annual shift saw Free Cash Flow tumbled 8343.95% in 2022 before it soared 355.63% in 2024.
  • A 5-year view of Free Cash Flow shows it stood at -$52.8 million in 2021, then tumbled by 89.51% to -$100.0 million in 2022, then skyrocketed by 87.03% to -$13.0 million in 2023, then skyrocketed by 320.55% to $28.6 million in 2024, then plummeted by 198.2% to -$28.1 million in 2025.
  • Per Business Quant, the three most recent readings for CHRS's Free Cash Flow are -$28.1 million (Q4 2025), -$46.3 million (Q3 2025), and $436.8 million (Q2 2025).